Clinical Benefit Analysis of Erdosteine plus azithromycin in comparsion to standard care in preventing exacerbation in recovered cases of acute exacerbation of Bronchiectasis (ERS 2026) - May 30, 2026 - Abstract #PA2887; Pres time: Sep 7, 2026; 08:00 AM - 09:30 AM; Location: PS-29; Board Number: 9; "Long-term azithromycin plus erdosteine significantly reduces exacerbation frequency, severity, and duration, while increasing exacerbation-free periods in bronchiectasis, with greatest benefit in severe disease."
Clinical • Bronchiectasis • Infectious Disease • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases
|
|
S. Patil; India; D. Muthreja; S. Patil; G. Gondhali; D. Kukarni; S. Tak; G. Narwade; M. Bhadake; A. Kuwal
|